Nano-X Imaging (NASDAQ: NNOX), the Israeli X-ray imaging company that hopes to disrupt the medical devices market with a business model charging per X-ray delivered rather than simply selling X-ray machines, jumped in Thursday trading, rising 14.2% through 12:30 p.m. ET.
Why? This morning, Nano-X announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to use its Nanox.ARC X technology to produce "tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indications" -- and presumably, to charge per image.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Nano-X says its proprietary Nanox.ARC X technology uses artificial intelligence in conjunction with 2D X-ray scans to produce "a more comprehensive, sliced three-dimensional view of the body." (Yes, you read that right. Nano-X is an artificial intelligence company now.)
It's also moving quickly to build out a market for its services. The company noted that the FDA granted 510(k) clearance "less than 30 days from the date of submission" of its request. The company further notes that a Nanox.ARC X system itself is plug-and-play and can be installed in a medical location in just a single day.
Unprofitable today, with $53.5 million in trailing-12-month losses and about $39 million in annual cash burn, Nano-X is the kind of growth stock that must move quickly to justify its valuation -- and replenish its cash.
Winning FDA clearance for its proprietary 3D technology is only the first step in achieving that growth, however. Now, the company needs to demonstrate a demand for its services, which can translate into rapid sales growth and eventually profits.
Last year, Nano-X grew sales at a respectable 14%, a good start. Still, looking ahead, Wall Street analysts polled by S&P Global Market Intelligence don't see the company turning profitable before 2028 (although free cash flow may arrive sooner). Right now, whether Nano-X is a buy depends a lot on whether it can start generating cash...before it burns through the $73 million in cash it already has.
Before you buy stock in Nano-X Imaging, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nano-X Imaging wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $518,599!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $640,429!*
Now, it’s worth noting Stock Advisor’s total average return is 791% — a market-crushing outperformance compared to 152% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of April 14, 2025
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.